1
|
Hashmi SK, Powles RC, Ma D, Muhsen IN, Aljurf M, Niederwieser D, Weisdorf DJ, Koh MBC, Greinix H. Radiation hazards of the Ukraine nuclear power plants: how can international blood and marrow stem cell transplant societies help? Ann Hematol 2024; 103:1121-1129. [PMID: 37280449 DOI: 10.1007/s00277-023-05191-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2022] [Accepted: 12/18/2022] [Indexed: 06/08/2023]
Abstract
Any conflict in countries that process nuclear power plants raises concerns of the potential radiation injuries to the people in that region and beyond such as the current conflict in Ukraine. International healthcare organizations and societies should prepare for the potential scenarios of nuclear incidents. The Worldwide Network for Blood and Marrow Transplantation (WBMT) and its members, have recent experience preparing for this type of events such as the Fukushima incident in 2011. In this article, we discuss the risks of radiation exposure, current guidelines, and scientific evidence on hematopoietic support, including the role of hematopoietic stem cell transplant (HCT) for those exposed to nuclear radiation, and the role that the WBMT and other global BMT societies can play in triaging and managing people suffering from radiation injuries.
Collapse
Affiliation(s)
- Shahrukh K Hashmi
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Medicine, Sheikh Shakbout Medical City, Abu Dhabi, UAE.
- College of Medicine & Health Sciences, Khalifa University, Abu Dhabi, UAE.
| | - Ray C Powles
- Cancer Centre London, 49 Parkside, Wimbledon, London, SW19 5NB, UK
| | - David Ma
- Department of Haematology, St Vincent's Hospital, Darlinghurst, NSW, Australia
| | - Ibrahim N Muhsen
- Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Mahmoud Aljurf
- Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Dietger Niederwieser
- University of Leipzig, Leipzig, Germany
- Aichi Medical University, Nagakute, Japan
| | - Daniel J Weisdorf
- Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA
| | - Mickey B C Koh
- Infection and Immunity Clinical Academic Group, St George's University of London, London, UK
- Department of Haematology, St George's University Hospitals, London, UK
- Cell Therapy Programme, Health Sciences Authority, Outram, Singapore
| | - Hildegard Greinix
- Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| |
Collapse
|
2
|
Muhsen IN, Galeano S, Niederwieser D, Koh MBC, Ljungman P, Machado CM, Kharfan-Dabaja MA, de la Camara R, Kodera Y, Szer J, Rasheed W, Cesaro S, Hashmi SK, Seber A, Atsuta Y, Saleh MFM, Srivastava A, Styczynski J, Alrajhi A, Almaghrabi R, Abid MB, Chemaly RF, Gergis U, Brissot E, El Fakih R, Riches M, Mikulska M, Worel N, Weisdorf D, Greinix H, Cordonnier C, Aljurf M. Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review. The Lancet Haematology 2023; 10:e284-e294. [PMID: 36990623 DOI: 10.1016/s2352-3026(23)00032-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 11/04/2022] [Accepted: 01/18/2023] [Indexed: 03/29/2023]
Abstract
Literature discussing endemic and regionally limited infections in recipients of haematopoietic stem-cell transplantation (HSCT) outside western Europe and North America is scarce. This Worldwide Network for Blood and Marrow Transplantation (WBMT) article is part one of two papers aiming to provide guidance to transplantation centres around the globe regarding infection prevention and treatment, and considerations for transplantation based on current evidence and expert opinion. These recommendations were initially formulated by a core writing team from the WBMT and subsequently underwent multiple revisions by infectious disease experts and HSCT experts. In this paper, we summarise the data and provide recommendations on several endemic and regionally limited viral and bacterial infections, many of which are listed by WHO as neglected tropical diseases, including Dengue, Zika, yellow fever, chikungunya, rabies, brucellosis, melioidosis, and leptospirosis.
Collapse
|
3
|
Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBC, Kröger N, Mohty M, Galeano S, Okamoto S, Chaudhri N, Karduss AJ, Ciceri F, Colturato VAR, Corbacioglu S, Elhaddad A, Force LM, Frutos C, León AGD, Hamad N, Hamerschlak N, He N, Ho A, Huang XJ, Jacobs B, Kim HJ, Iida M, Lehmann L, de Latour RP, Percival MEM, Perdomo M, Rasheed W, Schultz KR, Seber A, Ko BS, Simione AJ, Srivastava A, Szer J, Wood WA, Kodera Y, Nagler A, Snowden JA, Weisdorf D, Passweg J, Pasquini MC, Sureda A, Atsuta Y, Aljurf M, Niederwieser D. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther 2023; 29:279.e1-279.e10. [PMID: 36572384 DOI: 10.1016/j.jtct.2022.12.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 12/16/2022] [Accepted: 12/16/2022] [Indexed: 12/25/2022]
Abstract
Acute myeloid leukemia (AML) has an aggressive course and a historically dismal prognosis. For many patients, hematopoietic stem cell transplantation (HSCT) represents the best option for cure, but access, utilization, and health inequities on a global scale remain poorly elucidated. We wanted to describe patterns of global HSCT use in AML for a better understanding of global access, practices, and unmet needs internationally. Estimates of AML incident cases in 2016 were obtained from the Global Burden of Disease 2019 study. HSCT activities were collected from 2009 to 2016 by the Worldwide Network for Blood and Marrow Transplantation through its member organizations. The primary endpoint was global and regional use (number of HSCT) and utilization of HSCT (number of HSCT/number of incident cases) for AML. Secondary outcomes included trends from 2009 to 2016 in donor type, stem cell source, and remission status at time of HSCT. Global AML incidence has steadily increased, from 102,000 (95% uncertainty interval: 90,200-108,000) in 2009 to 118,000 (104,000-126,000) in 2016 (16.2%). Over the same period, a 54.9% increase from 9659 to 14,965 HSCT/yr was observed globally, driven by an increase in allogeneic (64.9%) with a reduction in autologous (-34.9%) HSCT. Although the highest numbers of HSCT continue to be performed in high-resource regions, the largest increases were seen in resource-constrained regions (94.6% in Africa/East Mediterranean Region [AFR/EMR]; 34.7% in America-Nord Region [AMR-N]). HSCT utilization was skewed toward high-resource regions (in 2016: AMR-N 18.4%, Europe [EUR] 17.9%, South-East Asia/Western Pacific Region [SEAR/WPR] 11.7%, America-South Region [AMR-S] 4.5%, and AFR/EMR 2.8%). For patients <70 years of age, this difference in utilization was widened; AMR-N had the highest allogeneic utilization rate, increasing from 2009 to 2016 (30.6% to 39.9%) with continued low utilization observed in AFR/EMR (1.7% to 2.9%) and AMR-S (3.5% to 5.4%). Across all regions, total HSCT for AML in first complete remission (CR1) increased (from 44.1% to 59.0%). Patterns of donor stem cell source from related versus unrelated donors varied widely by geographic region. SEAR/WPR had a 130.2% increase in related donors from 2009 to 2016, and >95% HSCT donors in AFR/EMR were related; in comparison, AMR-N and EUR have a predilection for unrelated HSCT. Globally, the allogeneic HSCT stem cell source was predominantly peripheral blood (69.7% of total HSCT in 2009 increased to 78.6% in 2016). Autologous HSCT decreased in all regions from 2009 to 2016 except in SEAR/WPR (18.9%). HSCT remains a central curative treatment modality in AML. Allogeneic HSCT for AML is rising globally, but there are marked variations in regional utilization and practices, including types of graft source. Resource-constrained regions have the largest growth in HSCT use, but utilization rates remain low, with a predilection for familial-related donor sources and are typically offered in CR1. Further studies are necessary to elucidate the reasons, including economic factors, to understand and address these health inequalities and improve discrepancies in use of HSCT as a potentially curative treatment globally.
Collapse
Affiliation(s)
- Molly C Tokaz
- Division of Medical Oncology, University of Washington, Seattle, Washington; Division of Hematology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
| | - Helen Baldomero
- University Hospital Basel, Center for International Blood and Marrow Transplant Research, Switzerland
| | - Andrew J Cowan
- Division of Medical Oncology, University of Washington, Seattle, Washington; Division of Hematology, University of Washington, Seattle, Washington
| | - Wael Saber
- Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
| | | | - Mickey B C Koh
- Infection and Immunity Clinical Academic Group, St George's Hospital and Medical School, London, United Kingdom; Academic Cell Therapy Facility and Programme Health Sciences Authority, Singapore
| | | | - Mohamad Mohty
- Sorbonne University, Hospital Saint Antoine, Paris, France
| | - Sebastian Galeano
- Latin American Blood and Marrow Transplantation Group - LABMT Hospital Británico, Montevideo, Uruguay
| | - Shinichiro Okamoto
- Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Naeem Chaudhri
- King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Amado J Karduss
- Clínica Las Américas, Latin AmericanBlood and Marrow Transplantation Group- LABMT, Medellín, Colombia
| | - Fabio Ciceri
- University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | | | | | - Alaa Elhaddad
- African Blood and Marrow Transplantation Group - AfBMT; Department of Pediatric Oncology and Stem Cell Transplantation Unit, Cairo University, Cairo, Egypt
| | - Lisa M Force
- Division of Pediatric Hematology-Oncology, Department of Pediatrics and Department of Health Metrics Sciences, University of Washington, Seattle, Washington
| | | | | | - Nada Hamad
- Department of Haematology, St. Vincent's Hospital Sydney, School of Clinical Medicine, Faculty of Medicine and Health, UNSW, School of Medicine, University of Notre Dame Australia, Sydney, Australia
| | | | - Naya He
- University Hospital Basel, Center for International Blood and Marrow Transplant Research, Switzerland
| | - Aloysius Ho
- Department of Haematology, Singapore General Hospital, Singapore
| | - Xiao-Jun Huang
- Department of Hematology, Peking University Institute of Hematology, Beijing, China
| | - Ben Jacobs
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - Hee-Je Kim
- Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Minako Iida
- Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan
| | - Leslie Lehmann
- Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
| | | | - Mary-Elizabeth M Percival
- Division of Hematology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington
| | | | - Walid Rasheed
- King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Kirk R Schultz
- BC Children's Hospital/UBC, Vancouver, British Columbia, Canada
| | - Adriana Seber
- Latin American Blood and Marrow Transplantation Group-LABMT, Bern, Switzerland; Hospital Samaritano - Americas, Sao Paulo Brazil and Pediatric Oncology Institute-Graacc-Unifesp, São Paulo, Brazil
| | - Bor-Sheng Ko
- Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
| | | | | | - Jeff Szer
- Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), St. Vincent ́s Hospital Sydney, Sydney, New South Wales, Australia; Peter MacCallum Cancer Center and Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - William A Wood
- CIBMTR, University of North Carolina, Chapel Hill, North Carolina
| | - Yoshihisa Kodera
- Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan
| | - Arnon Nagler
- The Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - John A Snowden
- Department of Hematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
| | - Daniel Weisdorf
- CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota
| | - Jakob Passweg
- University Hospital Basel, Center for International Blood and Marrow Transplant Research, Switzerland
| | - Marcelo C Pasquini
- Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Anna Sureda
- Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
| | - Yoshiko Atsuta
- Japanese Data Center for Hematopoietic Cell Transplantation, Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan
| | - Mahmoud Aljurf
- King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Dietger Niederwieser
- University Leipzig, Leipzig, Germany; Japanese Data Center for Hematopoietic Cell Transplantation, Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan; KaunoKlinikos University of Health Sciences, Kaunas, Lithuania
| |
Collapse
|
4
|
Muhsen IN, Galeano S, Niederwieser D, Koh MBC, Ljungman P, Machado CM, Kharfan-Dabaja MA, de la Camara R, Kodera Y, Szer J, Rasheed W, Cesaro S, Hashmi SK, Seber A, Atsuta Y, Saleh MFM, Srivastava A, Styczynski J, Alrajhi A, Almaghrabi R, Abid MB, Chemaly RF, Gergis U, Brissot E, El Fakih R, Riches M, Mikulska M, Worel N, Weisdorf D, Greinix H, Cordonnier C, Aljurf M. Endemic or regionally limited parasitic and fungal infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review. The Lancet Haematology 2023; 10:e295-e305. [PMID: 36990624 DOI: 10.1016/s2352-3026(23)00031-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 11/17/2022] [Accepted: 01/18/2023] [Indexed: 03/29/2023]
Abstract
There is a scarcity of data on endemic and regionally limited fungal and parasitic infections in recipients of haematopoietic stem-cell transplantation (HSCT) outside western Europe and North America. This Worldwide Network for Blood and Marrow Transplantation (WBMT) Review is one of two papers aiming to provide guidance to transplantation centres worldwide regarding prevention, diagnosis, and treatment based on the currently available evidence and expert opinion. These recommendations were created and reviewed by physicians with expertise in HSCT or infectious disease, representing several infectious disease and HSCT groups and societies. In this paper, we review the literature on several endemic and regionally limited parasitic and fungal infections, some of which are listed as neglected tropical diseases by WHO, including visceral leishmaniasis, Chagas disease, strongyloidiasis, malaria, schistosomiasis, histoplasmosis, blastomycosis, and coccidioidomycosis.
Collapse
Affiliation(s)
- Ibrahim N Muhsen
- Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | | | - Dietger Niederwieser
- Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany; Lithuanian University of Health Sciences Kauno Klinikos, Lithuania; Aichi Medical University School of Medicine, Nagakute, Japan
| | - Mickey B C Koh
- Infection and Immunity Clinical Academic Group, University of London and Department of Haematology, St George's Hospital and Medical School, London, UK; Cell Therapy Facility, Blood Services Group, Health Sciences Authority, Singapore
| | - Per Ljungman
- Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Clarisse M Machado
- Virology Laboratory Institute of Tropical Medicine-University of São Paulo Medical School, São Paulo, Brazil; HCT Program - Hospital Amaral Carvalho, Jahu, Brazil
| | | | | | - Yoshihisa Kodera
- Center for Hematopoietic Stem Cell Transplantation, Aichi Medical University Hospital, Nagakute, Japan
| | - Jeff Szer
- Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Walid Rasheed
- Adult Hematology and Stem Cell Transplant, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Simone Cesaro
- Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Shahrukh K Hashmi
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Department of Medicine, Sheikh Shakbout Medical City, Abu Dhabi, United Arab Emirates; College of Medicine & Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates
| | - Adriana Seber
- Hospital Samaritano Higienópolis and Graacc - Unifesp, São Paulo, Brazil
| | - Yoshiko Atsuta
- Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; Department of Registry Science for Transplant and Cellular Therapy, Nagakute, Japan
| | - Mostafa F Mohammed Saleh
- Adult Hematology and Stem Cell Transplant, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Alok Srivastava
- Department of Hematology, Christian Medical College, Vellore, India; Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
| | - Jan Styczynski
- Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
| | - Abdulrahman Alrajhi
- Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Reem Almaghrabi
- Organ Transplantation Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Muhammad Bilal Abid
- Division of Divisions of Hematology/Oncology & Infectious Diseases, BMT & Cellular Therapy Program, Milwaukee, WI, USA
| | - Roy F Chemaly
- Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Usama Gergis
- Sidney Kimmel Cancer Center, Philadelphia, PA, USA
| | - Eolia Brissot
- Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France
| | - Riad El Fakih
- Adult Hematology and Stem Cell Transplant, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Marcie Riches
- Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Malgorzata Mikulska
- Division of Infectious Diseases, DISSAL, University of Genova, Italy and IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - Nina Worel
- Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria
| | - Daniel Weisdorf
- Division of Hematology, Oncology and Transplantation, University of Minnesota, MN, USA
| | | | - Catherine Cordonnier
- Haematology Department, Henri Mondor Hospital and University Paris-Est-Créteil, Créteil, France
| | - Mahmoud Aljurf
- Adult Hematology and Stem Cell Transplant, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
| |
Collapse
|
5
|
Gabriel C, Marks DC, Henschler R, Schallmoser K, Burnouf T, Koh MBC. Eye drops of human origin-Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies. Vox Sang 2023; 118:301-309. [PMID: 36847186 DOI: 10.1111/vox.13413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 02/06/2023] [Accepted: 02/07/2023] [Indexed: 03/01/2023]
Abstract
BACKGROUND AND OBJECTIVES Serum eye drops (SEDs) are used to treat ocular surface disease (OSD) and to promote ocular surface renewal. However, their use and production are not standardized, and several new forms of human eye drops have been developed. MATERIALS AND METHODS The International Society for Blood Transfusion Working Party (ISBT WP) for Cellular Therapies held a workshop to review the current types of eye drops of human origin (EDHO) status and provide guidance. RESULTS The ISBT WP for Cellular Therapies introduced the new terminology 'EDHO' to emphasize that these products are analogous to 'medical products of human origin'. This concept encompasses their source (serum, platelet lysate, and cord blood) and the increasingly diverse spectrum of clinical usage in ophthalmology and the need for traceability. The workshop identified the wide variability in EDHO manufacturing, lack of harmonized quality and production standards, distribution issues, reimbursement schemes and regulations. EDHO use and efficacy is established for the treatment of OSD, especially for those refractory to conventional treatments. CONCLUSION Production and distribution of single-donor donations are cumbersome and complex. The workshop participants agreed that allogeneic EDHO have advantages over autologous EDHO although more data on clinical efficacy and safety are needed. Allogeneic EDHOs enable more efficient production and, when pooled, can provide enhanced standardization for clinical consistency, provided optimal margin of virus safety is ensured. Newer products, including platelet-lysate- and cord-blood-derived EDHO, show promise and benefits over SED, but their safety and efficacy are yet to be fully established. This workshop highlighted the need for harmonization of EDHO standards and guidelines.
Collapse
Affiliation(s)
- Christian Gabriel
- Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.,Ludwig Boltzmann Institute for Clinical and Experimental Traumatology, Vienna, Austria
| | - Denese C Marks
- Research and Development, The Australian Red Cross Lifeblood, Sydney, Australia.,Sydney Medical School, The University of Sydney, Sydney, Australia
| | - Reinhard Henschler
- Institute of Transfusion Medicine, University Hospital and Medical Faculty, University of Leipzig, Leipzig, Germany
| | - Katharina Schallmoser
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.,Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria
| | - Thierry Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.,International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
| | - Mickey B C Koh
- Institute for Infection and Immunity, St. George's University of London, Cranmer Terrace, Jenner Wing, London, UK
| |
Collapse
|
6
|
Korenkova I, Bitan M, Klymenko S, Lysytsia O, Zaucha J, Mytilineos J, Haferlach T, Hochaus A, Heyman M, Guilhot F, Bolanos N, Kuts R, Greinix HI, Koh MBC, Landgraf S, Hehlmann R, Aljurf M, Sureda A, Rondelli D, Niederwieser D. Help for Ukrainian Hematology Patients (HUP): A Global Initiative Supporting Hematopoietic Stem Cell Transplantation (HSCT) Programs in a Time of Conflict. Transplant Cell Ther 2023. [DOI: 10.1016/s2666-6367(23)00467-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
7
|
Koh MBC, Halter JP, Greinix HT, Aljurf M, Worel N. Prioritising health equity alongside donation safety - Authors' reply. Lancet Haematol 2022; 9:e803-e804. [PMID: 36156201 DOI: 10.1016/s2352-3026(22)00302-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 09/07/2022] [Indexed: 06/16/2023]
Affiliation(s)
- Mickey B C Koh
- Infection and Immunity Institute, St George's, University of London, London, UK; Department of Haematology, St George's Hospital, London, UK; Cell Therapy Programme, Health Sciences Authority, Singapore, Singapore
| | - Jörg P Halter
- Department of Hematology, University Hospital Basel, Basel, University of Basel, Switzerland
| | | | - Mahmoud Aljurf
- Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Riyadh Province, Saudi Arabia
| | - Nina Worel
- Department of Blood Group Serology and Transfusion Medicine, Medical University Vienna, Vienna 1090, Austria.
| |
Collapse
|
8
|
Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, Shaw BE, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. Lancet Haematol 2022; 9:e605-e614. [PMID: 35901845 DOI: 10.1016/s2352-3026(22)00184-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 06/06/2022] [Accepted: 06/07/2022] [Indexed: 06/15/2023]
Abstract
The contribution of related donors to the globally rising number of allogeneic haematopoietic stem cell transplantations (HSCT) remains increasingly important, particularly because of the growing use of haploidentical HSCT. Compared with the strict recommendations on the suitability for unrelated donors, criteria for related donors allow for more discretion and vary between centres. In 2015, the donor outcome committee of the Worldwide Network for Blood and Marrow Transplantation (WBMT) proposed consensus recommendations of suitability criteria for paediatric and adult related donors. This Review provides updates and additions to these recommendations from a panel of experts with global representation, including the WBMT, the European Society for Blood and Marrow Transplantation donor outcome committee, the Center for International Blood and Marrow Transplant Research donor health and safety committee, the US National Marrow Donor Program, and the World Marrow Donor Association, after review of the current literature and guidelines. Sections on the suitability of related donors who would not qualify as unrelated donors have been updated. Sections on communicable diseases, clonal haematopoiesis of indeterminate potential, paediatric aspects including psychological issues, and reporting on serious adverse events have been added. The intention of this Review is to support decision making, with the goal of minimising the medical risk to the donor and protecting the recipient from transmissible diseases.
Collapse
Affiliation(s)
- Nina Worel
- Department of Blood Group Serology and Transfusion Medicine, Medical University Vienna, Vienna, 1090, Austria.
| | - Mahmoud Aljurf
- Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Riyadh Province, Saudi Arabia
| | - Chloe Anthias
- Anthony Nolan, London UK; Royal Marsden Hospital, London, UK
| | - Andreas S Buser
- Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland; Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Meghann Cody
- National Marrow Donor Program/Be The Match, Minneapolis, MN, USA
| | - Mirjam Fechter
- Matchis Foundation (the Dutch Centre for Stem Cell Donors), Leiden, the Netherlands
| | | | | | - Annika M Kisch
- Department of Haematology, Oncology, Radiation Physics, Skane University Hospital, Lund, Sweden; Institute of Health Sciences, Lund University, Sweden
| | - Mickey B C Koh
- Infection and Immunity Institute, St George's, University of London, London, UK; Department of Haematology, St George's Hospital, London, UK; Cell Therapy Programme, Health Sciences Authority, Singapore, Singapore
| | | | - Grazia Nicoloso
- Swiss Transfusion Swiss Red Cross, Swiss Blood Stem Cells, Bern, Switzerland
| | - Dietger Niederwieser
- Medical Clinic and Policlinic 1, Haematology, Cellular Therapy and Hemostaseology, Leipzig Medical Centre, University Leipzig, Leipzig, Germany
| | - Michael A Pulsipher
- Division of Pediatric Haematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute at the Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT, USA
| | - Adriana Seber
- Hospital Samaritano and Insituto de Oncologia Pediatrica - Graacc-Unifesp, São Paulo, Brazil
| | - Bronwen E Shaw
- Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | | | - Galen E Switzer
- Departments of Medicine, Psychiatry, and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA
| | - Jeff Szer
- Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Suzanna M van Walraven
- Department for Quality and Release Management, Sanquin Blood Bank, Amsterdam, Netherlands
| | - Hung Yang
- Australian Bone Marrow Donor Registry, Sydney, NSW, Australia
| | - Jörg P Halter
- Hematology, University Hospital Basel, University of Basel, Basel, Switzerland
| |
Collapse
|
9
|
Chan WY, Counsell N, de Tute R, De-Silva D, Phillips EH, Cavenagh J, Adedayo T, Braganca N, Roddie C, Streetly M, Schey S, Koh MBC, Crowe J, Morris TC, Cook G, Clifton-Hadley L, Rabin N, Owen RG, Popat R, Yong KL. Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. Br J Haematol 2021; 196:e33-e37. [PMID: 34636043 DOI: 10.1111/bjh.17903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 10/01/2021] [Accepted: 10/03/2021] [Indexed: 11/30/2022]
Affiliation(s)
- Wei Yee Chan
- University College London Hospitals NHS Foundation Trust, London, UK
| | | | | | | | - Elizabeth H Phillips
- Cancer Research UK & UCL Cancer Trials Centre, London, UK.,Division of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, Manchester, UK
| | | | - Toyin Adedayo
- Cancer Research UK & UCL Cancer Trials Centre, London, UK
| | | | - Claire Roddie
- University College London Hospitals NHS Foundation Trust, London, UK.,UCL Cancer Institute, London, UK
| | | | | | | | | | | | - Gordon Cook
- Leeds Cancer Centre and Leeds Institute of Clinical Trials Research, Leeds, UK
| | | | - Neil Rabin
- University College London Hospitals NHS Foundation Trust, London, UK
| | | | - Rakesh Popat
- University College London Hospitals NHS Foundation Trust, London, UK.,UCL Cancer Institute, London, UK
| | - Kwee L Yong
- University College London Hospitals NHS Foundation Trust, London, UK.,UCL Cancer Institute, London, UK
| | | |
Collapse
|
10
|
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica 2021. [PMID: 34382386 DOI: 10.3324/haematol.279189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries and individual centers. In 2016, 82,718 first HCTs were reported from 1662 HCT teams in 86 of the 195 World Health Organization member states representing a global increase of 6.2% in autologous and 7.0% in allogeneic HCT and bringing the total to 1,298,897 procedures. Assuming a frequency of 84,000/year, 1.5 million HCTs had been performed by 2019 from 1957. Slightly more autologous (53.5%) than allogeneic and more related (53.6%) than unrelated HCTs were reported. A remarkable increase was noted in haploidentical related HCT for leukemias and lymphoproliferative diseases, but even more in non-malignant diseases. Transplant rates (TR; HCT/10 million population) varied according to region reaching 560.8 in North America, 438.5 in Europe, 76.7 in Latin America, 53.6 in South East Asia/Western Pacific (SEA/WPR) and 27.8 in African/East Mediterranean (AFR/EMR). Interestingly, haploidentical TR amounted to 32% in SEA/WPR and 26% in Latin America, but only 14% in Europe and EMR and 4.9% in North America of all allogeneic HCT. HCT team density (teams/10 million population) was highest in Europe (7.7) followed by North America (6.0), SEA/WPR (1.9), Latin America (1.6) and AFR/EMR (0.4). HCTs are increasing steadily worldwide with narrowing gaps between regions and greater increase in allogeneic compared to autologous activity. While related HCT is rising, largely due to increase in haploidentical HCT, unrelated is plateauing and cord blood in decline.
Collapse
Affiliation(s)
- Dietger Niederwieser
- University, Leipzig, Germany; Aichi Medical University School of Medicine, Nagakute, Japan; Lithuanian University of Health Sciences, Kaunas.
| | - Helen Baldomero
- The Worldwide Network of Blood and Marrow Transplantation (WBMT) Transplant Activity Survey Office, University Hospital, Basel.
| | - Nosa Bazuaye
- African Blood and Marrow Transplantation Group - AfBMT; University of Benin Teaching Hospital, PMB 1111.
| | - Caitrin Bupp
- CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis.
| | - Naeem Chaudhri
- EMBMT and Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh.
| | - Selim Corbacioglu
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg.
| | - Alaa Elhaddad
- African Blood and Marrow Transplantation Group - AfBMT; Department of Pediatric Oncology and Stem Cell Transplantation Unit, Cairo University Cairo.
| | - Cristóbal Frutos
- Latin American Blood and Marrow Transplantation Group - LABMT; Cristóbal Frutos, Instituto de Previsión Social, Asunción.
| | - Sebastian Galeano
- Latin American Blood and Marrow Transplantation Group - LABMT; Sebastian Galeano, Hospital Británico, Montevideo.
| | - Nada Hamad
- Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), St. Vincent´s Hospital Sydney, Australia; St. Vincent's Health Network, Kinghorn Cancer Centre.
| | - Amir Ali Hamidieh
- The Eastern Mediterranean Blood and Marrow Transplant Group (EMBMT), King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Pediatric Cell Therapy Research Center Tehran University of Medical Sciences Tehran.
| | - Shahrukh Hashmi
- Sheikh Shakhbout Medical City, Abu Dhabi, UAE; MAYO Clinic, Rochester, MN.
| | - Aloysius Ho
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Singapore General Hospital Singapore.
| | | | - Minako Iida
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Aichi Medical University School of Medicine, Dept. of Promotion for Blood and Marrow Plantation, Nagakute. ;
| | - Gregorio Jaimovich
- Latin American Blood and Marrow Transplantation Group - LABMT; Fundación Favaloro, Sanatorio Anchorena, ITAC, Buenos Aires.
| | - Amado Karduss
- Latin American Blood and Marrow Transplantation Group - LABMT; Instituto de Cancerología-Clínica Las Américas, Medellín.
| | - Yoshihisa Kodera
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Aichi Medical University School of Medicine, Dept. of Promotion for Blood and Marrow Plantation, Nagakute. ;
| | - Nicolaus Kröger
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg.
| | - Regis Péffault de Latour
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75010 PARIS.
| | - Jong Wook Lee
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
| | - Juliana Martínez-Rolón
- Latin American Blood and Marrow Transplantation Group - LABMT; FUNDALEU, Buenos Aires, Argentina.
| | | | - Jakob Passweg
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Chefarzt Klinik für Hämatologie, Universitätsspital Basel, Petersgraben 4, 4031 Basel Switzerland.
| | - Kristjan Paulson
- CancerCare Manitoba and the University of Manitoba; Cell Therapy Transplant Canada (CTTC), Winnipeg, Manitoba.
| | - Adriana Seber
- Latin American Blood and Marrow Transplantation Group - LABMT; Pediatric Department, Hospital Samaritano, Sao Paulo.
| | - John A Snowden
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield.
| | - Alok Srivastava
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Christian Medical College, Vellore.
| | - Jeff Szer
- ABMTRR, St. Vincent Hospital, Sydney; Peter MacCallum Cancer and Royal Melbourne Hospital, Parkville.
| | - Daniel Weisdorf
- CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN; University of Minnesota, MMC 480, Minneapolis, MN 55455. ;
| | - Nina Worel
- Medical University of Vienna, Dept. of Blood Group Serology and Transfusion Medicine, Vienna.
| | - Mickey B C Koh
- Infection and Immunity Clinical Academic Group, St George's Hospital and Medical School, London; Academic Cell Therapy Facility and Programme Health Sciences Authority Singapore.
| | - Mahmoud Aljurf
- EMBMT and King Faisal Specialist Hospital and Research Center, Riyadh.
| | | | - Yoshiko Atsuta
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Nagoya.
| | - Wael Saber
- CIBMTR, Medical College of Wisconsin, Milwaukee. ; ;
| |
Collapse
|
11
|
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica 2021; 107:1045-1053. [PMID: 34382386 PMCID: PMC9052915 DOI: 10.3324/haematol.2021.279189] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Indexed: 11/22/2022] Open
Abstract
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries and individual centers. In 2016, 82,718 first HCT were reported by 1,662 HCT teams in 86 of the 195 World Health Organization member states representing a global increase of 6.2% in autologous HCT and 7.0% in allogeneic HCT and bringing the total to 1,298,897 procedures. Assuming a frequency of 84,000/year, 1.5 million HCT were performed by 2019 since 1957. Slightly more autologous (53.5%) than allogeneic and more related (53.6%) than unrelated HCT were reported. A remarkable increase was noted in haploidentical related HCT for leukemias and lymphoproliferative diseases, but even more in non-malignant diseases. Transplant rates (TR; HCT/10 million population) varied according to region reaching 560.8 in North America, 438.5 in Europe, 76.7 in Latin America, 53.6 in South East Asia/Western Pacific (SEA/WPR) and 27.8 in African/East Mediterranean (AFR/EMR). Interestingly, haploidentical TR amounted to 32% in SEA/WPR and 26% in Latin America, but only 14% in Europe and EMR and 4.9% in North America of all allogeneic HCT. HCT team density (teams/10 million population) was highest in Europe (7.7) followed by North America (6.0), SEA/WPR (1.9), Latin America (1.6) and AFR/EMR (0.4). HCT are increasing steadily worldwide with narrowing gaps between regions and greater increase in allogeneic compared to autologous activity. While related HCT is rising, largely due to increase in haploidentical HCT, unrelated HCT is plateauing and cord blood HCT is in decline.
Collapse
Affiliation(s)
- Dietger Niederwieser
- University, Leipzig, Germany; Aichi Medical University School of Medicine, Nagakute, Japan; Lithuanian University of Health Sciences, Kaunas.
| | - Helen Baldomero
- The Worldwide Network of Blood and Marrow Transplantation (WBMT) Transplant Activity Survey Office, University Hospital, Basel.
| | - Nosa Bazuaye
- African Blood and Marrow Transplantation Group - AfBMT; University of Benin Teaching Hospital, PMB 1111.
| | - Caitrin Bupp
- CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis.
| | - Naeem Chaudhri
- EMBMT and Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh.
| | - Selim Corbacioglu
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg.
| | - Alaa Elhaddad
- African Blood and Marrow Transplantation Group - AfBMT; Department of Pediatric Oncology and Stem Cell Transplantation Unit, Cairo University Cairo.
| | - Cristóbal Frutos
- Latin American Blood and Marrow Transplantation Group - LABMT; Cristóbal Frutos, Instituto de Previsión Social, Asunción.
| | - Sebastian Galeano
- Latin American Blood and Marrow Transplantation Group - LABMT; Sebastian Galeano, Hospital Británico, Montevideo.
| | - Nada Hamad
- Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), St. Vincent´s Hospital Sydney, Australia; St. Vincent's Health Network, Kinghorn Cancer Centre.
| | - Amir Ali Hamidieh
- The Eastern Mediterranean Blood and Marrow Transplant Group (EMBMT), King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Pediatric Cell Therapy Research Center Tehran University of Medical Sciences Tehran.
| | - Shahrukh Hashmi
- Sheikh Shakhbout Medical City, Abu Dhabi, UAE; MAYO Clinic, Rochester, MN.
| | - Aloysius Ho
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Singapore General Hospital Singapore.
| | | | - Minako Iida
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Aichi Medical University School of Medicine, Dept. of Promotion for Blood and Marrow Plantation, Nagakute. ;
| | - Gregorio Jaimovich
- Latin American Blood and Marrow Transplantation Group - LABMT; Fundación Favaloro, Sanatorio Anchorena, ITAC, Buenos Aires.
| | - Amado Karduss
- Latin American Blood and Marrow Transplantation Group - LABMT; Instituto de Cancerología-Clínica Las Américas, Medellín.
| | - Yoshihisa Kodera
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Aichi Medical University School of Medicine, Dept. of Promotion for Blood and Marrow Plantation, Nagakute. ;
| | - Nicolaus Kröger
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg.
| | - Regis Péffault de Latour
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75010 PARIS.
| | - Jong Wook Lee
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
| | - Juliana Martínez-Rolón
- Latin American Blood and Marrow Transplantation Group - LABMT; FUNDALEU, Buenos Aires, Argentina.
| | | | - Jakob Passweg
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Chefarzt Klinik für Hämatologie, Universitätsspital Basel, Petersgraben 4, 4031 Basel Switzerland.
| | - Kristjan Paulson
- CancerCare Manitoba and the University of Manitoba; Cell Therapy Transplant Canada (CTTC), Winnipeg, Manitoba.
| | - Adriana Seber
- Latin American Blood and Marrow Transplantation Group - LABMT; Pediatric Department, Hospital Samaritano, Sao Paulo.
| | - John A Snowden
- European Society for Blood and Marrow Transplantation (EBMT), Passeig Taulat 116, 08005, Barcelona, Spain; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield.
| | - Alok Srivastava
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Christian Medical College, Vellore.
| | - Jeff Szer
- ABMTRR, St. Vincent Hospital, Sydney; Peter MacCallum Cancer and Royal Melbourne Hospital, Parkville.
| | - Daniel Weisdorf
- CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN; University of Minnesota, MMC 480, Minneapolis, MN 55455. ;
| | - Nina Worel
- Medical University of Vienna, Dept. of Blood Group Serology and Transfusion Medicine, Vienna.
| | - Mickey B C Koh
- Infection and Immunity Clinical Academic Group, St George's Hospital and Medical School, London; Academic Cell Therapy Facility and Programme Health Sciences Authority Singapore.
| | - Mahmoud Aljurf
- EMBMT and King Faisal Specialist Hospital and Research Center, Riyadh.
| | | | - Yoshiko Atsuta
- The Asia Pacific Blood and Marrow Transplant Group (APBMT), Aichi Medical University School of Medicine, Nagakute, Japan; Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Nagoya.
| | - Wael Saber
- CIBMTR, Medical College of Wisconsin, Milwaukee. ; ;
| |
Collapse
|
12
|
Solves P, Lozano M, Zhiburt E, Anguita Velasco J, Maria Pérez-Corral A, Monsalvo-Saornil S, Yamazaki S, Okazaki H, Selleng K, Aurich K, Krüger W, Buser A, Holbro A, Infanti L, Stehle G, Pierelli L, Matteocci A, Rigacci L, De Vooght KMK, Kuball JHE, Fielding KL, Westerman DA, Wood EM, Cohn CS, Johnson A, Koh MBC, Qadir D, Cserti-Gazdewich C, Daguindau E, Angelot-Delettre F, Tiberghien P, Wendel-Neto S, Fachini RM, Morton S, Craddock C, Lumley M, Antoniewicz-Papis J, Hałaburda K, Łętowska M, Dunbar N. International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Summary. Vox Sang 2021; 116:609-612. [PMID: 33866564 DOI: 10.1111/vox.13061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Accepted: 12/02/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Pilar Solves
- Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Nancy Dunbar
- Dartmouth-Hitchcock Medical Center - Pathology, Lebanon, NH, USA
| |
Collapse
|
13
|
Solves P, Lozano M, Zhiburt E, Anguita Velasco J, Maria Pérez-Corral A, Monsalvo-Saornil S, Yamazaki S, Okazaki H, Selleng K, Aurich K, Krüger W, Buser A, Holbro A, Infanti L, Stehle G, Pierelli L, Matteocci A, Rigacci L, De Vooght KMK, Kuball JHE, Fielding KL, Westerman DA, Wood EM, Cohn CS, Johnson A, Koh MBC, Qadir D, Cserti-Gazdewich C, Daguindau E, Angelot-Delettre F, Tiberghien P, Wendel-Neto S, Fachini RM, Morton S, Craddock C, Lumley M, Antoniewicz-Papis J, Hałaburda K, Łętowska M, Dunbar N. International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses. Vox Sang 2021; 116:e25-e43. [PMID: 33866580 DOI: 10.1111/vox.13021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 10/01/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Pilar Solves
- Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | | | - Eugene Zhiburt
- Pirogov National Medical Surgical Center, Moscow, Russia
| | | | | | | | | | | | - Kathleen Selleng
- Institut für Immunologie und Transfusionsmedizin, Greifswald, Germany
| | - Konstanze Aurich
- Institut für Immunologie und Transfusionsmedizin, Greifswald, Germany
| | - William Krüger
- Klinik für Hämatologie und Onkologie, Universitätsmedizin Greifswald, Greifswald, Germany
| | - Andreas Buser
- Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland
| | - Andreas Holbro
- Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland
| | - Laura Infanti
- Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland
| | - Gregor Stehle
- Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland
| | - Luca Pierelli
- Sapienza University, Rome, Italy.,San Camillo Forlanini Hospital, Rome, Italy
| | | | | | | | | | - Katherine L Fielding
- Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Vic, Australia
| | | | - Erica M Wood
- Peter MacCallum Cancer Centre, Parkville, Vic, Australia
| | | | | | | | - Dara Qadir
- St George's University Hospital, London, UK
| | | | | | | | | | | | | | | | - Charles Craddock
- University Hospitals Birmingham NHS Foundation Trust, Sutton Coldfield, UK
| | - Matthew Lumley
- University Hospitals Birmingham NHS Foundation Trust, Sutton Coldfield, UK
| | | | | | | | - Nancy Dunbar
- Dartmouth-Hitchcock Medical Center - Pathology, Lebanon, NH, USA
| |
Collapse
|
14
|
Popat R, Counsell N, de Tute R, De-Silva D, Phillips EH, Cavenagh JD, Adedayo T, Braganca N, Roddie C, Streetly M, Schey S, Koh MBC, Crowe J, Morris TC, Cook G, Smith P, Clifton-Hadley L, Rabin N, Owen R, Yong K. Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. Br J Haematol 2021; 193:e19-e22. [PMID: 33715154 DOI: 10.1111/bjh.17391] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 02/14/2021] [Indexed: 11/26/2022]
Affiliation(s)
- Rakesh Popat
- UCL Cancer Institute, London, UK.,University College London Hospitals NHS Foundation Trust, London, UK
| | | | - Ruth de Tute
- Leeds Cancer Centre, Leeds Teaching Hospital NHS Trust, Leeds, UK
| | | | - Elizabeth H Phillips
- Cancer Research UK & UCL Cancer Trials Centre, London, UK.,Division of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, Manchester, UK
| | | | - Toyin Adedayo
- Cancer Research UK & UCL Cancer Trials Centre, London, UK
| | | | | | | | | | - Mickey B C Koh
- St George's University Hospitals NHS Foundation Trust, London, UK
| | | | | | - Gordon Cook
- Leeds Cancer Centre, Leeds Teaching Hospital NHS Trust, Leeds, UK
| | - Paul Smith
- Cancer Research UK & UCL Cancer Trials Centre, London, UK
| | | | - Neil Rabin
- University College London Hospitals NHS Foundation Trust, London, UK
| | - Roger Owen
- Leeds Cancer Centre, Leeds Teaching Hospital NHS Trust, Leeds, UK
| | | | | |
Collapse
|
15
|
Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant 2019; 55:698-707. [PMID: 31484992 DOI: 10.1038/s41409-019-0658-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 06/28/2019] [Accepted: 07/05/2019] [Indexed: 12/18/2022]
Abstract
Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.
Collapse
Affiliation(s)
- Ibrahim N Muhsen
- Department of Medicine, Houston Methodist Hospital, Houston, TX, USA
| | - Shahrukh K Hashmi
- Hematology Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. .,Department of Medicine, Mayo Clinic, Rochester, MN, USA.
| | - Dietger Niederwieser
- Department of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany
| | - Nicolaus Kroeger
- Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - Samir Agrawal
- Division of Haemato-Oncology, Bart's Health NHS Trust and Blizard Institute, Queen Mary University of London, London, UK
| | - Marcelo C Pasquini
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI, USA
| | - Yoshiko Atsuta
- Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan
| | - Karen K Ballen
- Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA
| | | | - Wael Saber
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI, USA
| | - Mohamed A Kharfan-Dabaja
- Department of Medicine, Division of Hematology-Oncology and Blood and Marrow Transplantation program, Mayo Clinic, Jacksonville, FL, USA
| | - Walid Rasheed
- Hematology Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
| | | | - Nandita Khera
- Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA
| | - William A Wood
- Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA
| | | | | | - Yoshihisa Kodera
- Center for Hematopoietic Stem Cell Transplantation, Aichi Medical University Hospital, Nagakute, Japan
| | - Jeff Szer
- Department of Clinical Haematology, Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Mary M Horowitz
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI, USA
| | | | - Mahmoud Aljurf
- Hematology Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
| |
Collapse
|
16
|
Schallmoser K, Henschler R, Gabriel C, Koh MBC, Burnouf T. Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion. Trends Biotechnol 2019; 38:13-23. [PMID: 31326128 DOI: 10.1016/j.tibtech.2019.06.002] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 06/12/2019] [Accepted: 06/12/2019] [Indexed: 12/28/2022]
Abstract
Human platelet lysate (HPL), rich in growth factors, is an efficient alternative supplement to fetal bovine serum (FBS) for ex vivo propagation of stromal cell-based medicinal products. Since 2014, HPL has been a focus of the Working Party for Cellular Therapies of the International Society of Blood Transfusion (ISBT). Currently, as several Good Manufacturing Practice (GMP)-compliant manufacturing protocols exist, an international consensus defining the optimal modes of industrial production, product specification, pathogen safety, and release criteria of this ancillary material (AM) is needed. This opinion article by the ISBT Working Party summarizes the current knowledge on HPL production and proposes recommendations on manufacturing and quality management in line with current technological innovations and regulations of biological products and advanced therapy medicinal products.
Collapse
Affiliation(s)
- Katharina Schallmoser
- Department of Transfusion Medicine, and Spinal Cord Injury and Tissue Regeneration Center Salzburg (Sci-TReCS), Paracelsus Medical University, Salzburg, Austria.
| | - Reinhard Henschler
- Institute of Transfusion Medicine, University Hospital Leipzig AöR, Leipzig, Germany
| | - Christian Gabriel
- Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria; Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Mickey B C Koh
- St George's Hospital and Medical School, London, UK; Cell Therapy Facility, Blood Services Group, Health Sciences Authority, Singapore
| | - Thierry Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
| |
Collapse
|
17
|
Luah YH, Sundar Raj K, Koh MBC, Linn YC. A novel simplified method of generating cytomegalovirus-specific cytokine-induced killer cells of high specificity and superior potency with GMP compliance. Clin Immunol 2019; 205:83-92. [PMID: 31229666 DOI: 10.1016/j.clim.2019.06.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2018] [Revised: 04/07/2019] [Accepted: 06/19/2019] [Indexed: 12/13/2022]
Abstract
We describe a method of rendering polyclonal cytokine-induced killer cells (CIK) specific against cytomegalovirus (CMV), focusing on GMP compliance. Peripheral blood mononuclear cells (PBMNC) are stimulated with pooled CMV peptides pp65 and IE-1 for 16-24 h and the reactive T cell subset which up-regulate CD137 is further co-stimulated with anti-CD137, followed by expansion in G-Rex flasks under standard CIK culture condition. This method generates a large number CMV-specific CIK with superior potency compared to published method currently in clinical trials. The cytotoxicity as measured by chromium release assay correlates with the upregulation of CD107a upon peptide re-challenge as measured by flow cytometry. CMV-CIK at maturity consist of mainly late effector memory CD8 T cells and have a skewed TCR repertoire with preferential expansion of a few families. Such CMV-CIK retain their function after freezing and thawing. CMV-CIK thus generated is ready for clinical trial against drug-resistant CMV disease.
Collapse
Affiliation(s)
- Yen Hoon Luah
- Cell Therapy Facility, Health Sciences Authority, 11 Outram Rd, 169078, Singapore
| | | | - Mickey B C Koh
- Cell Therapy Facility, Health Sciences Authority, 11 Outram Rd, 169078, Singapore
| | - Yeh Ching Linn
- Dept of Hematology, Singapore General Hospital, Outram Rd, 169608, Singapore.
| |
Collapse
|
18
|
Henschler R, Gabriel C, Schallmoser K, Burnouf T, Koh MBC. Human platelet lysate current standards and future developments. Transfusion 2019; 59:1407-1413. [PMID: 30741431 DOI: 10.1111/trf.15174] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 12/13/2018] [Indexed: 11/30/2022]
Abstract
A state-of-the-art workshop focused on the use of human platelet lysate (HPL) for cell therapy. The meeting established that HPL is used mainly as an adjunct material for ex vivo expansion of mesenchymal stem/progenitor cells (MSCs), where it is successfully used as a substitute for fetal bovine serum. HPL manufacturing as a cell expansion supplement is currently not yet uniformly standardized with regard to platelet source and production methodology. There are very few reports of HPL preparations manufactured specifically for direct clinical use. There exists an urgent need for controlled clinical studies for HPL and for standardization of product definition. Workshop participants also stated a need for consensus minimum release criteria to allow for better product definition and to limit variability in performance. The increasing use of cell-based therapies including MSCs has led to an increasing demand for HPL, either produced in blood establishments or large-scale manufacture by biopharmaceutical companies. The use of pooled donor platelets for HPL production may require the implementation of pathogen inactivation procedures and/or removal steps to improve the safety of advanced cell therapy products. There should also be a requirement for thorough risk assessments and risk mitigation steps, including the qualification of suppliers and identification of ingredients as well as meticulous monitoring of product quality and safety profiles. State-of-the-art regulatory approaches for HPL used for human cell propagation and PRP in direct clinical applications were reviewed.
Collapse
Affiliation(s)
- Reinhard Henschler
- Institute of Transfusion Medicine, University Hospital Leipzig, Leipzig, Germany
| | - Christian Gabriel
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Katharina Schallmoser
- Department of Transfusion Medicine, and Spinal Cord Injury and Tissue Regeneration Center Salzburg (Sci-TReCS), Paracelsus Medical University, Salzburg, Austria
| | - Thierry Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.,International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.,International PhD Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Mickey B C Koh
- St George's Hospital and Medical School, London, United Kingdom.,Cell Therapy Facility, Blood Services Group, Health Sciences Authority, Singapore
| |
Collapse
|
19
|
Cuende N, Rasko JEJ, Koh MBC, Dominici M, Ikonomou L. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy 2018; 20:1401-1413. [PMID: 30366616 DOI: 10.1016/j.jcyt.2018.09.010] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Accepted: 09/24/2018] [Indexed: 10/28/2022]
Abstract
Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The International Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with marketing authorization (MA) in different regions. This article reflects the dynamic momentum around authorized CGTs coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous scientific and regulatory assessment and authorization. This is intended to be a living document with a yearly update linked to a dedicated section of the ISCT website for faster adjustments. The aim is to ultimately inform, by periodic snapshots, the scientific community, healthcare stakeholders and patient associations on authorized CGT products as a way to increase communication around the approved therapeutic approaches charged with heightened expectations.
Collapse
Affiliation(s)
- Natividad Cuende
- Andalusian Initiative for Advanced Therapies, Junta de Andalucía, Seville, Spain; Andalusian Transplant Coordination, Servicio Andaluz de Salud, Seville, Spain.
| | - John E J Rasko
- Sydney Medical School, University of Sydney, Sydney, Australia; Gene and Stem Cell Therapy Program, Centenary Institute, Sydney, Australia; Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, New South Wales, Australia; International Society for Cell & Gene Therapy (ISCT) President
| | - Mickey B C Koh
- Department of Haematology, St George's Hospital and Medical School, London, UK; Blood Services Group, Health Sciences Authority, Singapore
| | - Massimo Dominici
- Division of Oncology, Laboratory of Cellular Therapy, University of Modena & Reggio Emilia, Modena, Italy; Chair, ISCT Presidential Task Force on the Use of Unproven Cellular Therapies
| | - Laertis Ikonomou
- The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA; Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts, USA.
| |
Collapse
|
20
|
Youngstein T, B C Koh M, Ros Soto J, Rowczenio D, Trojer H, Lachmann HJ, Sofat N. Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting as transfusion-dependent refractory haemophagocytosis. Rheumatology (Oxford) 2018; 57:582-583. [PMID: 29228362 DOI: 10.1093/rheumatology/kex427] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2017] [Indexed: 11/14/2022] Open
Affiliation(s)
- Taryn Youngstein
- National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, London, UK
| | - Mickey B C Koh
- Department of Haematology, St George's University Hospitals NHS Foundation Trust, London, UK
| | - Jose Ros Soto
- Department of Haematology, St George's University Hospitals NHS Foundation Trust, London, UK
| | - Dorota Rowczenio
- National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, London, UK
| | - Hadija Trojer
- National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, London, UK
| | - Helen J Lachmann
- National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, London, UK
| | - Nidhi Sofat
- Institute for Infection & Immunity, St George's University of London and Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, UK
| |
Collapse
|
21
|
Koh MBC. Considerations in setting up and planning a graft processing facility. Hematol Oncol Stem Cell Ther 2017; 10:195-197. [PMID: 29248695 DOI: 10.1016/j.hemonc.2017.12.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 03/30/2017] [Indexed: 11/24/2022] Open
Abstract
The graft processing facility forms one of the core components of a clinical haematopoietic stem cell transplant program. The quality of a graft is instrumental in leading to consistent and reproducible outcomes of engraftment and other parameters. As such, meticulous planning and consideration is required and will include core elements including physical design and clinical correlates. The successful running of such a facility depends on an overarching quality program and adherence to local and international regulatory guidelines.
Collapse
Affiliation(s)
- Mickey B C Koh
- Dept of Haematology, St George's University NHS Foundation Trust, London, UK; Cell Therapy Facility, Health Sciences Authority, Singapore.
| |
Collapse
|
22
|
Rovó A, Kulasekararaj A, Medinger M, Chevallier P, Ribera JM, Peffault de Latour R, Knol C, Iacobelli S, Kanfer E, Bruno B, Maury S, Quarello P, Koh MBC, Schouten H, Blau IW, Tichelli A, Hill A, Risitano A, Passweg J, Marsh J, Dreger P, Dufour C. Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. Br J Haematol 2017; 184:294-298. [PMID: 29265360 DOI: 10.1111/bjh.15074] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Alicia Rovó
- University Hospital of Bern, Bern, Switzerland
| | | | | | | | - Jose M Ribera
- Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain
| | | | - Cora Knol
- EBMT Data Office, Leiden, the Netherlands
| | - Simona Iacobelli
- Centro Interdipartimentale di Biostatistica e Bioinformatica, Università Tor Vergata, Rome, Italy
| | | | | | | | | | | | | | - Igor W Blau
- Charité - Campus Virchow Klinikum, Berlin, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Youngs J, Suarez C, Koh MBC. An unusual presentation of neutropenic enterocolitis (typhlitis). Lancet Infect Dis 2016; 16:618. [PMID: 27599654 DOI: 10.1016/s1473-3099(15)00399-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 09/25/2015] [Accepted: 10/09/2015] [Indexed: 10/21/2022]
Affiliation(s)
- Jonathan Youngs
- Department of Infectious Diseases, St George's Hospital, London, UK.
| | - Cristina Suarez
- Department of Infectious Diseases, St George's Hospital, London, UK; Infection and Immunity Institute, St George's University of London, London, UK
| | - Mickey B C Koh
- Department of Haematology, St George's Hospital, London, UK
| |
Collapse
|
24
|
Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MBC, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 2015; 18:151-9. [PMID: 26724220 DOI: 10.1016/j.jcyt.2015.11.008] [Citation(s) in RCA: 343] [Impact Index Per Article: 38.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Revised: 11/17/2015] [Accepted: 11/17/2015] [Indexed: 02/08/2023]
Abstract
Mesenchymal stromal cells (MSCs) as a pharmaceutical for ailments characterized by pathogenic autoimmune, alloimmune and inflammatory processes now cover the spectrum of early- to late-phase clinical trials in both industry and academic sponsored studies. There is a broad consensus that despite different tissue sourcing and varied culture expansion protocols, human MSC-like cell products likely share fundamental mechanisms of action mediating their anti-inflammatory and tissue repair functionalities. Identification of functional markers of potency and reduction to practice of standardized, easily deployable methods of measurements of such would benefit the field. This would satisfy both mechanistic research as well as development of release potency assays to meet Regulatory Authority requirements for conduct of advanced clinical studies and their eventual registration. In response to this unmet need, the International Society for Cellular Therapy (ISCT) addressed the issue at an international workshop in May 2015 as part of the 21st ISCT annual meeting in Las Vegas. The scope of the workshop was focused on discussing potency assays germane to immunomodulation by MSC-like products in clinical indications targeting immune disorders. We here provide consensus perspective arising from this forum. We propose that focused analysis of selected MSC markers robustly deployed by in vitro licensing and metricized with a matrix of assays should be responsive to requirements from Regulatory Authorities. Workshop participants identified three preferred analytic methods that could inform a matrix assay approach: quantitative RNA analysis of selected gene products; flow cytometry analysis of functionally relevant surface markers and protein-based assay of secretome. We also advocate that potency assays acceptable to the Regulatory Authorities be rendered publicly accessible in an "open-access" manner, such as through publication or database collection.
Collapse
Affiliation(s)
- Jacques Galipeau
- Department of Hematology and Medical Oncology, Winship Cancer Institute, and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
| | - Mauro Krampera
- Section of Hematology, Stem Cell Research Laboratory and Cell Factory, Department of Medicine, University of Verona, Verona, Italy
| | - John Barrett
- Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
| | - Francesco Dazzi
- Regenerative and Heamatological Medicine, King's College London, London, UK
| | - Robert J Deans
- Regenerative Medicine, Athersys Inc., Cleveland, OH, USA
| | - Joost DeBruijn
- School of Engineering and Materials Science, Queen Mary University of London, London, UK
| | - Massimo Dominici
- Department of Medical and Surgical Sciences for Children and Adults, Division of Oncology, University-Hospital of Modena and Reggio Emilia, Modena, Italy
| | - Willem E Fibbe
- Department of Immunohematology and Bloodtransfusion, Leiden University Medical Centre, Leiden, Netherlands
| | - Adrian P Gee
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Houston, TX, USA
| | - Jeffery M Gimble
- Center for Stem Cell Research and Regenerative Medicine, Department of Medicine, and Department of Surgery, Tulane University School of Medicine, New Orleans, LA, USA
| | - Peiman Hematti
- Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, and University of Wisconsin Carbone Cancer Center, Madison, WI, USA
| | - Mickey B C Koh
- Department of Haematology, St George's Hospital and Medical School, London, UK; Blood Services Group, Health Sciences Authority, Singapore
| | - Katarina LeBlanc
- Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Ivan Martin
- Department of Biomedicine, University Hospital Basel, Basel, Switzerland
| | - Ian K McNiece
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | | | - Steve Oh
- Stem Cell Group, Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR), Singapore
| | - Luis Ortiz
- Division of Occupational and Environmental Health Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
| | - Donald G Phinney
- Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA
| | - Valerie Planat
- IFR150 STROMALab UMR 5273 UPS-CNRS-EFS-INSERM U1031, Toulouse, France
| | - Yufang Shi
- Institute of Health Sciences, Chinese Academy of Sciences, Shanghai, China; The First Affiliated Hospital, Soochow University Institutes for Translational Medicine, Suzhou, China
| | - David F Stroncek
- Cell Processing Section, Department of Transfusion Medicine Clinical Center, NIH, Bethesda, MD, USA
| | | | - Daniel J Weiss
- Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
| | - Luc Sensebe
- UMR5273 STROMALab CNRS/EFS/UPS-INSERM U1031, Toulouse, France
| |
Collapse
|
25
|
Burnouf T, Strunk D, Koh MBC, Schallmoser K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials 2015; 76:371-87. [PMID: 26561934 DOI: 10.1016/j.biomaterials.2015.10.065] [Citation(s) in RCA: 318] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 10/16/2015] [Accepted: 10/26/2015] [Indexed: 02/07/2023]
Abstract
The essential physiological role of platelets in wound healing and tissue repair builds the rationale for the use of human platelet derivatives in regenerative medicine. Abundant growth factors and cytokines stored in platelet granules can be naturally released by thrombin activation and clotting or artificially by freeze/thaw-mediated platelet lysis, sonication or chemical treatment. Human platelet lysate prepared by the various release strategies has been established as a suitable alternative to fetal bovine serum as culture medium supplement, enabling efficient propagation of human cells under animal serum-free conditions for a multiplicity of applications in advanced somatic cell therapy and tissue engineering. The rapidly increasing number of studies using platelet derived products for inducing human cell proliferation and differentiation has also uncovered a considerable variability of human platelet lysate preparations which limits comparability of results. The main variations discussed herein encompass aspects of donor selection, preparation of the starting material, the possibility for pooling in plasma or additive solution, the implementation of pathogen inactivation and consideration of ABO blood groups, all of which can influence applicability. This review outlines the current knowledge about human platelet lysate as a powerful additive for human cell propagation and highlights its role as a prevailing supplement for human cell culture capable to replace animal serum in a growing spectrum of applications.
Collapse
Affiliation(s)
- Thierry Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
| | - Dirk Strunk
- Experimental & Clinical Cell Therapy Institute, Paracelsus Medical University, Salzburg, Austria; Spinal Cord Injury & Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria.
| | - Mickey B C Koh
- Blood Services Group, Health Sciences Authority, Singapore; Department for Hematology, St George's Hospital and Medical School, London, UK
| | - Katharina Schallmoser
- Spinal Cord Injury & Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria; Department for Blood Group Serology and Transfusion Medicine, Paracelsus Medical University, Salzburg, Austria.
| |
Collapse
|
26
|
Cesaro S, Peffault de Latour R, Tridello G, Pillon M, Carlson K, Fagioli F, Jouet JP, Koh MBC, Panizzolo IS, Kyrcz-Krzemien S, Maertens J, Rambaldi A, Strahm B, Blaise D, Maschan A, Marsh J, Dufour C. Second allogeneic stem cell transplant for aplastic anaemia: a retrospective study by the Severe Aplastic Anaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol 2015; 171:606-14. [PMID: 26304743 DOI: 10.1111/bjh.13650] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2015] [Accepted: 07/23/2015] [Indexed: 12/15/2022]
Abstract
We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162 patients reported to the European Society for Blood and Marrow Transplantation between 1998 and 2009. Donor origin was a sibling in 110 and an unrelated donor in 52 transplants, respectively. The stem cell source was bone marrow in 31% and peripheral blood in 69% of transplants. The same donor as for the first alloHSCT was used in 81% of transplants whereas a change in the choice of stem cell source was reported in 56% of patients, mainly from bone marrow to peripheral blood. Neutrophil and platelet engraftment occurred in 85% and 72% of patients, after a median time of 15 and 17 days, respectively. Grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD occurred in 21% and 37% of patients, respectively. Graft failure (GF) occurred in 42 patients (26%). After a median follow-up of 3·5 years, the 5-year overall survival (OS) was 60·7%. In multivariate analysis, the only factor significantly associated with a better outcome was a Karnofsky/Lansky score ≥80 (higher OS). We conclude that a second alloHSCT is feasible rescue option for GF in SAA, with a successful outcome in 60% of cases.
Collapse
Affiliation(s)
- Simone Cesaro
- Paediatric Haematology and Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | | | - Gloria Tridello
- Paediatric Haematology and Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - Marta Pillon
- Clinica di Oncoematologia Pediatrica Dipartimento di Pediatria, Padova, Italy
| | | | - Franca Fagioli
- Paediatric Haematology, Regina Margherita Hospital, Torino, Italy
| | - Jean-Pierre Jouet
- Hôpital Claude Huriez Service de Maladies du Sang, Lille Cedex, France
| | - Mickey B C Koh
- St. George's Hospital Department of Haematology, London, UK
| | - Irene Sara Panizzolo
- Paediatric Haematology and Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | | | - Johan Maertens
- Dept. of Haematology, University Hospital Gasthuisberg, Leuven, Belgium
| | | | - Brigitte Strahm
- Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine, University Medical Centre, Freiburg, Germany
| | - Didier Blaise
- Programme de Transplantation &Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
| | - Alexei Maschan
- Federal Research Centre for Paediatric Haematology, Oncology and Immunology, Moscow, Russia
| | - Judith Marsh
- Department of Haematological Medicine, King's College Hospital/King's College London, London, UK
| | - Carlo Dufour
- Paediatric Haematology, Institute G. Gaslini, Genova, Italy
| | | |
Collapse
|
27
|
Marsh JC, Pearce RM, Koh MBC, Lim Z, Pagliuca A, Mufti GJ, Perry J, Snowden JA, Vora AJ, Wynn RT, Russell N, Gibson B, Gilleece M, Milligan D, Veys P, Samarasinghe S, McMullin M, Kirkland K, Cook G. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2013; 49:42-8. [PMID: 23912664 DOI: 10.1038/bmt.2013.115] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 05/28/2013] [Accepted: 06/26/2013] [Indexed: 11/09/2022]
Abstract
This retrospective national study compared the use of alemtuzumab-based conditioning regimens for hematopoietic SCT (HSCT) in acquired severe aplastic anemia with antithymocyte globulin (ATG)-based regimens. One hundred patients received alemtuzumab and 55 ATG-based regimens. A matched sibling donor (MSD) was used in 87 (56%), matched unrelated donor (MUD) in 60 (39%) and other related or mismatched unrelated donor (UD) in 8 (5%) patients. Engraftment failure occurred in 9% of the alemtuzumab group and 11% of the ATG group. Five-year OS was 90% for the alemtuzumab and 79% for the ATG groups, P=0.11. For UD HSCT, OS of patients was better when using alemtuzumab (88%) compared with ATG (57%), P=0.026, although smaller numbers of patients received ATG. Similar outcomes for MSD HSCT using alemtuzumab or ATG were seen (91% vs 85%, respectively, P=0.562). A lower risk of chronic GVHD (cGVHD) was observed in the alemtuzumab group (11% vs 26%, P=0.031). On multivariate analysis, use of BM as stem cell source was associated with better OS and EFS, and less acute and cGVHD; young age was associated with better EFS and lower risk of graft failure. This large study confirms successful avoidance of irradiation in the conditioning regimens for MUD HSCT patients.
Collapse
Affiliation(s)
- J C Marsh
- Department of Haematological Medicine, King's College Hospital and King's College London,, London, UK
| | - R M Pearce
- BSBMT Data Registry, Guy's Hospital, London, UK
| | - M B C Koh
- Department of Haematology, St George's Hospital and Medical School, London, UK
| | - Z Lim
- Department of Haematology-Oncology, National University Cancer Institute, National Hospital Singapore, Singapore
| | - A Pagliuca
- Department of Haematological Medicine, King's College Hospital and King's College London,, London, UK
| | - G J Mufti
- Department of Haematological Medicine, King's College Hospital and King's College London,, London, UK
| | - J Perry
- BSBMT Data Registry, Guy's Hospital, London, UK
| | - J A Snowden
- 1] Department of Haematology, Sheffield Teaching Hospitals, Sheffield, UK [2] Department of Oncology, University of Sheffield, Sheffield, UK
| | - A J Vora
- Department of Haematology, Sheffield Children's Hospital, Sheffield, UK
| | - R T Wynn
- Department of Paediatric Blood and Marrow Transplant, Royal Manchester Children's Hospital, Manchester, UK
| | - N Russell
- Department of Haematology, Nottingham University Hospital, Nottingham, UK
| | - B Gibson
- Department of Haematology, Royal Hospital for Sick Children, Glasgow, Scotland, UK
| | - M Gilleece
- Department of Haematology, St James's Institute of Oncology, St James's University Hospital, Leeds, UK
| | - D Milligan
- Centre for Haematology and Transplantation, Heartlands Hospital, Birmingham, UK
| | - P Veys
- Department of Haematology, Great Ormond Hospital for Sick Children, London, UK
| | - S Samarasinghe
- Department of Paediatric and Adolescent Haematology, Great North Children's Hospital, Newcastle-Upon-Tyne, UK
| | - M McMullin
- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK
| | - K Kirkland
- BSBMT Data Registry, Guy's Hospital, London, UK
| | - G Cook
- Department of Haematology, St James's Institute of Oncology, St James's University Hospital, Leeds, UK
| | | |
Collapse
|
28
|
Abstract
Cellular immunotherapy has been widely accepted as a new powerful modality of cancer treatment. The last 2 decades have seen impressive results in its application against haemato-oncologic malignancies, melanomas and prostate carcinoma. Cellular immunotherapy has since found applicability beyond cancer into autoimmunity and continues to expand in its clinical applicability. The discovery that stem cells have the ability to differentiate into more mature cell types, like neurones and myocardium, has focused research on using exogenous cells to repair damaged tissues. This led to numerous clinical trials using stem cells in myocardial infarction, cardiomyopathy and spinal cord damage. Results have ranged from modest to significant clinical outcomes with continuing debate on the exact process of regeneration achieved. The intertwining between cell therapy and transfusion medicine now includes research on progenitor cells for the production of mature red cells. It is also clear that cell therapy has enabled an improved understanding of the pathogenesis and clinical course of many diseases, while perhaps its role in regenerative medicine is most enticing. However, the critical role of manufacturing in terms of cost, complexity, reproducibility, and regulatory matters remains a central issue in the consideration of whether cell therapy has met all of its promise.
Collapse
Affiliation(s)
- Mickey B C Koh
- Blood Services Group, Health Sciences Authority, Singapore.
| | | |
Collapse
|
29
|
Suck G, Oei VYS, Linn YC, Ho SH, Chu S, Choong A, Niam M, Koh MBC. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp Hematol 2011; 39:904-14. [PMID: 21703984 DOI: 10.1016/j.exphem.2011.06.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2010] [Revised: 05/30/2011] [Accepted: 06/07/2011] [Indexed: 10/18/2022]
Abstract
OBJECTIVE Interleukin (IL)-15 is a promising novel cytokine for natural killer (NK) cell activation and survival. We studied the effects of IL-15 compared to IL-2 on NK cells in long-term cultures for clinical translation. MATERIALS AND METHODS CD56(+)CD3(-) NK cells were expanded with IL-2 or IL-15 for 2 to 4 weeks within lymphokine-activated killer (LAK) cell cultures (LAK-NK) in serum-enriched AIM V or CellGro Stem Cell Growth Medium (SCGM). Cell growth, viability, and NK cell content were monitored and cytotoxicity assessed in a flow cytometric cytotoxicity assay. RESULTS IL-15 (100-1000 U/mL) could replace IL-2 (1000 U/mL) in AIM V cultures to achieve efficient LAK cell expansion. However, IL-15-stimulated LAK cells exceeded cytotoxicity of IL-2-stimulated LAK cells against K562, notably at later culture points. In the powerful CellGro SCGM, LAK cells expanded over 28 days an average of 905-fold ± 320-fold standard error of the mean (SEM) for IL-2 (500 U/mL) and 484-fold ± 98-fold SEM for IL-15 (500 U/mL), and NK cells within such LAK cultures expanded an average of 2320-fold ± 975-fold SEM for IL-2 and 1084-fold ± 309-fold SEM for IL-15. Importantly, such IL-15-activated LAK-NK cells retained enhanced cytotoxicity at later culture points against K562 as well. IL-15-stimulated effectors were also highly cytotoxic against hematological targets MOLT-4 and KU812 and nontoxic against autologous nonmalignant cells. Interestingly, IL-15-LAK-NK cells showed overall significant upregulation of the main activating and inhibitory NK cell receptors after long-term cytokine stimulation. CONCLUSIONS Our results demonstrate the potential for IL-15 to support large-scale expansion of clinical-grade LAK-NK effectors, which could retain enhanced longer-term potency and preserve activation receptors in therapy of hematological malignancies. Protocols are readily clinically translatable.
Collapse
Affiliation(s)
- Garnet Suck
- Blood Services Group, Health Sciences Authority, Singapore.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Hwang WYK, Piu Koh L, Lim ST, Ching Linn Y, Loh YS, Koh MBC, Phipps Diong C, Jing Lee J, Hui Zhang X, Rajgor D, Gandhi M, Shah A, Goh YT. Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphoma. Leuk Lymphoma 2011; 52:1382-6. [DOI: 10.3109/10428194.2011.569038] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
31
|
Suck G, Tan SM, Chu S, Niam M, Vararattanavech A, Lim TJ, Koh MBC. KHYG-1 and NK-92 represent different subtypes of LFA-1-mediated NK cell adhesiveness. Front Biosci (Elite Ed) 2011; 3:166-178. [PMID: 21196295 DOI: 10.2741/e230] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Novel cancer cellular therapy approaches involving long-term ex vivo IL-2 stimulated highly cytotoxic natural killer (NK) cells are emerging. However, adhesion properties of such NK cells are not very well understood. Herein, we describe the novel observation of permanently activated alphaLbeta2 integrin leukocyte function-associated antigen (LFA)-1 adhesion receptor in long-term IL-2 activated NK cells and the permanent NK cell lines KHYG-1 and NK-92. We show that such cytokine activated NK effectors constitutively adhered to the LFA-1-ligand ICAM-1, whereas binding to the lower affinity ligand ICAM-3 required additional exogenous activating conditions. The results demonstrate an extended conformation and an intermediate affinity state for the LFA-1 population expressed by the NK cells. Interestingly, adhesion to ICAM-1 or K562 induced pronounced cell spreading in KHYG-1, but not in NK-92, and partially in long-term IL-2 stimulated primary NK cells. It is conceivable that such differential adhesion characteristics may impact motility potential of such NK effectors with relevance to clinical tumor targeting. KHYG-1 could be a useful model in planning future targeted therapeutic approaches involving NK effectors with augmented functions.
Collapse
Affiliation(s)
- Garnet Suck
- Blood Services Group, Health Sciences Authority, Singapore.
| | | | | | | | | | | | | |
Collapse
|
32
|
Suck G, Veljkovic V, Chu S, Niam M, Tan SM, Branch DR, Koh MBC. Vasoactive intestinal peptide 10-28 enhances natural killer cell cytotoxicity (134.84). The Journal of Immunology 2009. [DOI: 10.4049/jimmunol.182.supp.134.84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Objective: Vasoactive intestinal peptide (VIP) and its synthetic analog VIP14-28 enhance NK cytotoxicity. This prompted us to study interaction of the naturally occurring peptide and orphan ligand VIP 10-28 with NK.
Results: VIP10-28 stimulation (10-8-10-10 M, 30 min.) increased NK-92 cytotoxicity against K562 max. from 52% +/-2.6% SEM (control) to 68% +/-2.6% SEM (E:T 1:1), similar to long-term IL-2 stimulated NK from different donors (4/6), max. from 38% +/-4.2 SEM (control) to 51% +/-0.9% SEM (E:T 1:1). VIP10-28 did not seem to induce degranulation, since granzyme B levels remained unchanged in NK-92. However, stimulation with 10-8-10-10 M VIP10-28 for 5- 60 min. significantly induced tyrosine phosphorylation with ERK identified as one of the stimulated kinases. We used Informational Spectrum Method (ISM) to predict VIP10-28 NK receptor interactions. ISM results suggested potential binding of VIP10-28 to LFA-1α (F = 0.03, peptide residues 16-24) and with lower affinity to CD44 or MAC-1, but unlikely to NKG2D, -C, -A, NKp30, -44, -46, CD56, CD94, KIR2DL4, NKR-P1, CD45 or VIP receptors VPAC-1/ VPAC-2.
Conclusion: The neuroendocrine peptide VIP10-28 induces increased NK cytotoxicity potentially through LFA-1 signaling pathways involving tyrosine kinase activation of ERK kinases.
Collapse
Affiliation(s)
- Garnet Suck
- 1Blood Services Group, Health Sciences Authority, Singapore, Singapore
| | - Veljko Veljkovic
- 2Centre for Multidisciplinary Research, Institute of Nuclear Sciences VINCA, Belgrade, Yugoslavia
| | - Sixian Chu
- 1Blood Services Group, Health Sciences Authority, Singapore, Singapore
| | - Madelaine Niam
- 1Blood Services Group, Health Sciences Authority, Singapore, Singapore
| | - Suet Mien Tan
- 3School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
| | - Donald R. Branch
- 4Research and Development, Canadian Blood Services, Toronto, Ontario Canada
| | - Mickey B. C. Koh
- 1Blood Services Group, Health Sciences Authority, Singapore, Singapore
- 5Department for Haematology, Singapore General Hospital, Singapore, Singapore
| |
Collapse
|
33
|
Koh MBC, Goh YT, Tan PHC, Koh LP, Hwang WYK, Loh Y, Tan D, Ng HJ, Chuah C, Lim TJ, Niam M, Suck G, Chan M, Phang CY, Lee JJ, Wee V, Ng HY, Lim CH, Yiu R, Kam G, Ang A, Linn YC. Stem cell transplantation programme at Singapore General Hospital. Bone Marrow Transplant 2008; 42 Suppl 1:S121-S124. [DOI: 10.1038/bmt.2008.139] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
34
|
Koh LP, Koh MBC, Ng HY, Hwang WYK, Goh YT, Linn YC, Ng HJ, Chuah CTH, Tan KW, Loh YSM, Tan DCL, Tan PHC, Tan PHC. Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia Following Nonmyeloablative Conditioning Using 200-cGy Total Body Irradiation and Fludarabine. Biol Blood Marrow Transplant 2006; 12:887-90. [PMID: 16864060 DOI: 10.1016/j.bbmt.2006.04.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2006] [Accepted: 04/15/2006] [Indexed: 11/20/2022]
|
35
|
Abstract
Excess perioperative bleeding remains a major complication following surgery, resulting in increased morbidity and mortality. The principal causes of non-surgical haemostatic perioperative bleeding are a pre-existing undetected bleeding disorder, related to the nature of the operation itself or from coagulation abnormalities arising from massive blood loss. Very often, it is a combination and coexistence of various pathologies. Identifying patients at risk remains a major component of preventing excessive blood loss. Understanding the haemostatic changes occurring in the perioperative period, especially in complex procedures like cardiopulmonary bypass and orthotopic liver transplantation is crucial in developing new strategies for the management of perioperative bleeding. Pharmacological interventions, especially aprotinin, tranexamic acid, desmopressin and increasingly, recombinant VIIa are being used both in prophylaxis and therapeutically to stop bleeding. The use of near patient testing like thromboelastography and platelet function analyser has allowed for more detailed assessment of the various steps of haemostasis. One of the main goals is to reduce the usage of allogeneic blood transfusion and its attendant risks.
Collapse
Affiliation(s)
- M B C Koh
- Department of Haematology, Guy's and St. Thomas' Trust, London, UK
| | | |
Collapse
|
36
|
Koh MBC, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol 2002; 118:108-16. [PMID: 12100133 DOI: 10.1046/j.1365-2141.2002.03682.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Graft-versus-host disease (GvHD) is a multistep immune process involving lymphocyte activation, proliferation and target cell killing. We have devised a novel method for the selective depletion of alloreactive cells from haematopoietic stem cell grafts which retains a pool of immunocompetent lymphocytes possessing antiviral activity with the potential to hasten immune reconstitution. The method is based upon the expression of the activation antigen CD69 on responding donor lymphocytes in a cytokine-modified mixed lymphocyte culture (mMLC) and depletion of these cells by paramagnetic bead sorting. We have previously demonstrated the in vitro efficacy of this system for the removal of alloreactive cells in both human leucocyte antigen-mismatched and -matched settings. Here, we describe a non-obese diabetic/severe combined immunodeficient murine model of aggressive GvHD in which we have tested its in vivo efficacy. Murine recipients of infusions of non-manipulated major histocompatibility complex class I and class II mismatched donor T cells suffered rapid onset of acute, and generally fatal, GvHD. This model is akin to aggressive clinical transfusion-related GvHD. Recipients of lymphocyte infusions depleted of CD69+ alloreactive donor cells ex vivo and monitored for 10 weeks post infusion demonstrated significantly improved survival (71.4% compared with 12.5% in the non-manipulated group) and the absence of clinical GvHD despite the presence of circulating donor lymphocytes.
Collapse
Affiliation(s)
- Mickey B C Koh
- Department of Haematology, Royal Free Campus, Royal Free and University College Medical School, London, UK
| | | | | | | | | | | |
Collapse
|